Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL), following the company's continued progress in building clinical evidence for IHL-42X in obstructive sleep apnea (OSA). The update comes after the release of full Phase 2 RePOSA data and exit-interview analyses, which demonstrated statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus placebo for both low and high-dose IHL-42X. Notably, the high-dose arm achieved maximum AHI reductions of up to 83%.
Exit interviews further supported the drug's potential, with 57.6% of participants reporting perceived improvement in their OSA, and most describing the change as meaningful to daily life. IHL-42X was well tolerated across both dose cohorts, reinforcing its potential for broad use. Additionally, Incannex reported $68.9 million in cash and cash equivalents, providing a strong financial foundation for continued development.
Incannex also received Fast Track designation from the FDA for IHL-42X, which may expedite its development and review process. The positive Phase 2 results for PSX-001, another candidate in the pipeline, further bolster the company's portfolio. For more details, view the full announcement here.
Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations, equity research, and institutional investor outreach services. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. The updated coverage reflects Incannex's progress in addressing OSA, a condition affecting millions worldwide.
